N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide

C22H30N6O3 — CID 110195537

IUPACN-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide
SMILESO=C(NC1CCN(C(=O)N2C[C@H]3C[C@H](C2)[C@H]2CCCC(=O)N2C3)CC1)c1cnccn1
InChIInChI=1S/C22H30N6O3/c29-20-3-1-2-19-16-10-15(13-28(19)20)12-27(14-16)22(31)26-8-4-17(5-9-26)25-21(30)18-11-23-6-7-24-18/h6-7,11,15-17,19H,1-5,8-10,12-14H2,(H,25,30)/t15-,16-,19-/m1/s1
InChIKeyDGQNLESKCGFIDH-GPMSIDNRSA-N
MW426.52 g/mol
LogP1.12
Rot. Bonds2

About N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide

N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide (PubChem CID 110195537) has the molecular formula C22H30N6O3 and a molecular weight of 426.52 g/mol. Its IUPAC name is N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide.

Molecular Properties

Compound NameN-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide
PubChem CID110195537
Molecular FormulaC22H30N6O3
Molecular Weight426.52 g/mol
Exact Mass426.24
IUPAC NameN-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide
SMILESO=C(NC1CCN(C(=O)N2C[C@H]3C[C@H](C2)[C@H]2CCCC(=O)N2C3)CC1)c1cnccn1
InChIInChI=1S/C22H30N6O3/c29-20-3-1-2-19-16-10-15(13-28(19)20)12-27(14-16)22(31)26-8-4-17(5-9-26)25-21(30)18-11-23-6-7-24-18/h6-7,11,15-17,19H,1-5,8-10,12-14H2,(H,25,30)/t15-,16-,19-/m1/s1
InChIKeyDGQNLESKCGFIDH-GPMSIDNRSA-N
XLogP1.12
TPSA98.74 Ų
H-Bond Donors1
H-Bond Acceptors5
Rotatable Bonds2
Heavy Atoms31
Complexity

Lipinski Rule of Five

Passes Rule of Five

RuleValue
MW ≤ 500426.52
LogP ≤ 51.12
H-Bond Donors ≤ 51
H-Bond Acceptors ≤ 105

Analyze N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide with MolForge

Explore ADMET properties, 3D molecular structure, drug-likeness score, and discover similar compounds using our AI-powered platform.

Launch Full Analysis

Frequently Asked Questions

What is the IUPAC name of N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide?
The IUPAC name of N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide (CID 110195537) is N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide.
What is the SMILES notation for N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide?
The canonical SMILES for N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide is O=C(NC1CCN(C(=O)N2C[C@H]3C[C@H](C2)[C@H]2CCCC(=O)N2C3)CC1)c1cnccn1.
What is the InChIKey of N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide?
The InChIKey is DGQNLESKCGFIDH-GPMSIDNRSA-N. The full InChI is InChI=1S/C22H30N6O3/c29-20-3-1-2-19-16-10-15(13-28(19)20)12-27(14-16)22(31)26-8-4-17(5-9-26)25-21(30)18-11-23-6-7-24-18/h6-7,11,15-17,19H,1-5,8-10,12-14H2,(H,25,30)/t15-,16-,19-/m1/s1.
What are the key properties of N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide?
N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide has a molecular weight of 426.52 g/mol, XLogP of 1.12, 2 rotatable bonds, 1 hydrogen bond donors, and 5 hydrogen bond acceptors.
Where does this data come from?
All data for N-[1-[(1R,2R,9S)-6-oxo-7,11-diazatricyclo[7.3.1.02,7]tridecane-11-carbonyl]piperidin-4-yl]pyrazine-2-carboxamide is sourced from PubChem (CID 110195537), the world's largest open chemistry database maintained by the National Library of Medicine (NIH).